NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies today reported a 41 percent drop in cash receipts from customers in its fiscal second quarter compared with the previous quarter.
For the three-month period ended Dec. 31, Genetic Technologies' cash receipts fell to A$106,000 (US$85,765) from A$179,000 in fiscal Q1. Meanwhile, the company reported a 55 percent year-over-year drop in test samples received to 125 from 278. In the fiscal first quarter, the company received 115 test samples.